61 related articles for article (PubMed ID: 1688187)
1. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
2. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.
Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI
Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992
[TBL] [Abstract][Full Text] [Related]
3. Probing Structure and Function of Alkali Sensor IRR with Monoclonal Antibodies.
Goryashchenko AS; Mozhaev AA; Serova OV; Erokhina TN; Orsa AN; Deyev IE; Petrenko AG
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708676
[TBL] [Abstract][Full Text] [Related]
4. Specific visualization of tumor cells using upconversion nanophosphors.
Grebenik EA; Generalova AN; Nechaev AV; Khaydukov EV; Mironova KE; Stremovskiy OA; Lebedenko EN; Zvyagin AV; Deyev SM
Acta Naturae; 2014 Oct; 6(4):48-53. PubMed ID: 25558394
[TBL] [Abstract][Full Text] [Related]
5. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A
Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907
[TBL] [Abstract][Full Text] [Related]
6. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
[TBL] [Abstract][Full Text] [Related]
7. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
8. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
[TBL] [Abstract][Full Text] [Related]
9. Receptor blockade with monoclonal antibodies as anti-cancer therapy.
Baselga J; Mendelsohn J
Pharmacol Ther; 1994 Oct; 64(1):127-54. PubMed ID: 7846112
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
11. Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment.
Chikileva IO; Bruter AV; Persiyantseva NA; Zamkova MA; Vlasenko RY; Dolzhikova YI; Shubina IZ; Donenko FV; Lebedinskaya OV; Sokolova DV; Pokrovsky VS; Fedorova PO; Ustyuzhanina NE; Anisimova NY; Nifantiev NE; Kiselevskiy MV
Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37761005
[TBL] [Abstract][Full Text] [Related]
12. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
Moasser MM
Cancer Res; 2022 Aug; 82(16):2811-2820. PubMed ID: 35731927
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects.
Hanes V; Chow V; Stewart T; Puri A
Cancer Chemother Pharmacol; 2021 Nov; 88(5):879-886. PubMed ID: 34355250
[TBL] [Abstract][Full Text] [Related]
14. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
15. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
Di Modica M; Tagliabue E; Triulzi T
Dis Markers; 2017; 2017():7849108. PubMed ID: 29403144
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.
Prat M; Oltolina F; Basilico C
Biomedicines; 2014 Dec; 2(4):359-383. PubMed ID: 28548076
[TBL] [Abstract][Full Text] [Related]
17. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.
Wang H; Stoecklein NH; Lin PP; Gires O
Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128
[TBL] [Abstract][Full Text] [Related]
18. Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.
Kim WE; Yue B; Serrero G
Breast Cancer (Auckl); 2015; 9(Suppl 2):71-7. PubMed ID: 27168723
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.
O'Sullivan CC; Smith KL
Curr Breast Cancer Rep; 2014 Sep; 6(3):169-182. PubMed ID: 25285186
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
